Ann Arbor, United States
Sling Therapeutics, a clinical-stage company founded in 2020, is making significant strides in the biopharma and biotechnology industries. The company is headquartered in the United States and focuses on the late-stage development of an oral small molecule designed to treat thyroid eye disease (TED).
With a mission encapsulated in its slogan, "Focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED)", Sling Therapeutics leverages a robust team of highly experienced drug developers. The company's strategic counsel extends further, enriched by insights from a distinguished Scientific Advisory Board comprised of global experts.
In terms of financial traction, Sling Therapeutics secured a $35.00M investment during a Series A funding round on 13 June 2022. This strategic investment was led by The Rise Fund, signaling robust confidence in the potential breakthrough of Sling Therapeutics in treating TED.
